Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.

MLA

Shcherbinin, Sergey, et al. “Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.” JAMA Neurology, vol. 79, no. 10, Oct. 2022, pp. 1015–24. EBSCOhost, https://doi.org/10.1001/jamaneurol.2022.2793.

APA

Shcherbinin, S., Evans, C. D., Lu, M., Andersen, S. W., Pontecorvo, M. J., Willis, B. A., Gueorguieva, I., Hauck, P. M., Brooks, D. A., Mintun, M. A., & Sims, J. R. (2022). Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurology, 79(10), 1015–1024. https://doi.org/10.1001/jamaneurol.2022.2793

Chicago

Shcherbinin, Sergey, Cynthia D. Evans, Ming Lu, Scott W. Andersen, Michael J. Pontecorvo, Brian A. Willis, Ivelina Gueorguieva, et al. 2022. “Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.” JAMA Neurology 79 (10): 1015–24. doi:10.1001/jamaneurol.2022.2793.